{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-050077","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2022-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.656554+00:00","generated_at":"2026-06-27T05:37:16.286927+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cytek Q4 revenue $38.9M (+27% YoY); FY2021 revenue $128M (+38%); guides FY2022 $160-168M","bullets":["Q4 2021 revenue $38.9M (+27% YoY); FY2021 revenue $128.0M (+38% YoY).","Q4 net income $0.3M (vs $5.6M in Q4 2020); FY net income $4.4M (vs $19.4M in 2020).","Adjusted EBITDA Q4 $5.5M; FY $17.5M, up from $15.4M in 2020.","Installed base 1,110 instruments; 453 instrument placements in FY2021.","FY2022 revenue guidance $160-168M, representing 25-31% growth over FY2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-050077","json":"https://secwatch.observer/filing/0001193125-22-050077.json","markdown":"https://secwatch.observer/filing/0001193125-22-050077.md","text":"https://secwatch.observer/filing/0001193125-22-050077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312522050077/0001193125-22-050077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312522050077/d305036d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:37:16.286927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}